DS
DNLI icon

David Shaw’s Denali Therapeutics DNLI Stock Holding History

David Shaw’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-78,218
Closed -$1.06M – 4430
2025
Q1 		$1.06M Buy
+78,218
New +$1.5M ﹤0.01% 3050
2024
Q3 		– Sell
-29,721
Closed -$690K – 4604
2024
Q2 		$690K Sell
29,721
-86,544
-74% -$1.66M ﹤0.01% 3428
2024
Q1 		$2.39M Buy
+116,265
New +$2.19M ﹤0.01% 2488
2023
Q2 		– Sell
-44,336
Closed -$1.02M – 4302
2023
Q1 		$1.02M Sell
44,336
-90,091
-67% -$2.48M ﹤0.01% 3149
2022
Q4 		$3.74M Buy
+134,427
New +$4M ﹤0.01% 2365
2022
Q3 		– Sell
-86,113
Closed -$2.53M – 5258
2022
Q2 		$2.53M Buy
86,113
+79,865
+1,278% +$2.09M ﹤0.01% 2857
2022
Q1 		$201K Sell
6,248
-988
-14% -$34K ﹤0.01% 4864
2021
Q4 		$323K Sell
7,236
-38,177
-84% -$1.81M ﹤0.01% 4646
2021
Q3 		$2.29M Sell
45,413
-38,172
-46% -$2.15M ﹤0.01% 2907
2021
Q2 		$6.56M Sell
83,585
-122,577
-59% -$7.58M 0.01% 1825
2021
Q1 		$11.8M Buy
206,162
+126,802
+160% +$8.49M 0.01% 1252
2020
Q4 		$6.65M Sell
79,360
-65,658
-45% -$3.97M 0.01% 1660
2020
Q3 		$5.2M Buy
+145,018
New +$4.37M 0.01% 1659
2019
Q3 		– Sell
-102,274
Closed -$2.12M – 3846
2019
Q2 		$2.12M Buy
+102,274
New +$2.29M ﹤0.01% 2210

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

David Shaw's DNLI Position: Q2 2025 in Review

David Shaw sold out of Denali Therapeutics (DNLI) in Q2 2025, closing a stake of 78,218 shares — an estimated $1.06M sold.

David Shaw first reported a position in DNLI in Q2 2019 and held it in 14 quarters. The position peaked at $11.8M in Q1 2021. 230 funds tracked by Wall St. Rank hold DNLI as of Q2 2025.

  • David Shaw reported no remaining Denali Therapeutics position as of Q2 2025 after selling out during the quarter.
  • David Shaw sold 78,218 Denali Therapeutics shares in Q2 2025, an estimated $1.06M.
  • David Shaw first reported a position in Denali Therapeutics in Q2 2019 and held it in 14 quarters.
  • David Shaw's Denali Therapeutics position peaked at $11.8M in Q1 2021.
  • 230 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2025.

Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.